Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

wn as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's ENHANZE™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition to partnerships that use Halozyme's ENHANZE™ Technology, the Company has a number of product candidates in its pipeline that target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the commercial reintroduction of Hylenex, the timing, scope and outcomes of our clinical trials and presentation of data from our clinical trials, future regulatory submissions and PDUFA dates for our product candidates, expected financial results including anticipated operating expenses and net cash burn for FY 2011 as well as expected activities under our collaborative partnerships that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial results, regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact
Kurt Gustafson
Chief Financial Offi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., ... banking and therapeutics, announced today that StemCyte has become ... Indy car driven by James Jakes ... IndyCar 2013 season.   StemCyte, Inc. and Rahal ... of umbilical cord blood banking and its educational initiative ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 The New ... STEM industries, Black Data Processing Associates (BDPA), is hosting ... June 8, 2013. This all-day event will encourage students ... learn the ins and outs from many of the ... p.m. at the New Jersey Institute of Technology, the ...
(Date:5/23/2013)... SynCardia Systems, Inc. ( http://www.syncardia.com ), ... Canada and CE (Europe) approved Total Artificial Heart, announced ... boasts more than 380,000 visitors annually, is featuring the ... the Freedom® portable driver as part of its $3 ... of its kind. , “BodyWorks combines the latest ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... UPPSALA, Sweden, June 29 , ... Will Fund Gyros to Profitability , ... development, announces that it has raised SEK 80 million,(approximately euro ... Company,s leading shareholder. The new funds will enable Gyros to ...
... Kornberg Associates | Architects ( www.kornberg.com ) has ... new Cognitive & Neurobiological Imaging Center. Ken Kornberg, president ... with Stanford University since 1980 and has completed ... is the two-story, 32,000 square-foot office building for the Stanford ...
... ... elimination, exterior plastic trim and headlight restoration products to the Automotive, RV and Marine ... myriad of industries, to introduce these innovative and eco-friendly products to the pan-national marketplace. ... ...
Cached Biology Technology:Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 3
(Date:5/24/2013)... largest and fastest growing open-access publishers, today announces the ... . , A broad scope journal covering all specialties, ... and interactive web platform for the research community to ... Frontiers, real-time and interactive peer-review enables fast, fair and ... an average of three months from submission to final ...
(Date:5/24/2013)... to combat metastatic cancer , Cancer cells spread ... immune system. Stimulation of the immune system can help ... that cause the immune system to ignore cancer cells. ... suppress the immune system response. In this issue of ... by Ronald Levy at Stanford University found that regulatory ...
(Date:5/24/2013)... spread and grow by avoiding detection and destruction by ... help to eliminate cancer cells; however, there are many ... cells. Regulatory T cells are immune cells that function ... of the Journal of Clinical Investigation , researchers ... regulatory T cells that infiltrate tumors express proteins that ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8
... reproductive apparatus of a model virus is bolstering the idea ... important human diseases such as AIDS, SARS and hepatitis C ... vulnerable to broad-spectrum antiviral agents. In a study published ... of Science Biology, a team of researchers from the Howard ...
... 2007 It,s not a good idea to put all your ... in the parched Sonoran desert of southern Arizona and northern Mexico, ... senita cactus -- both for its food and for a place ... moth, the only species that pollinates its flowers. Senita cacti and ...
... In some ways, certain tumors resemble bee colonies, says pathologist ... specific role, and just a fraction of the cells serve ... an unspecialized state and seed new tumors. These cells can ... bulk of the tumor. These queens are cancer ...
Cached Biology News:Features of replication suggest viruses have common themes, vulnerabilities 2Features of replication suggest viruses have common themes, vulnerabilities 3Which came first, the moth or the cactus? 2Which came first, the moth or the cactus? 3Newly created cancer stem cells could aid breast cancer research 2Newly created cancer stem cells could aid breast cancer research 3
... Osteoclast cells form from a hematopoietic stem ... attaching to the bone surface and lowering ... of around 4.5. The bone mineral is ... differentiation and function is controlled primarily by ...
... Receptor-gamma (PPAR) is a member of ... transcription factors that heterodimerize with retinoic ... in the regulation of glucose and ... class of anti-diabetic agents called thiazolidinediones ...
... Nucleic acid hybridization Preparation ... mg BSA, 50 mg ficoll ... with 5 ml of water ... for molecular biology Density: 1.00 ...
... ProteinChip Antibody Capture Kit ... and optimization steps typically ... interactions. This kit enables ... of multiple antigens based ...
Biology Products: